blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3525823

EP3525823 - CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF PARKINSON'S DISEASE [Right-click to bookmark this link]
Former [2019/34]CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
[2023/26]
StatusThe patent has been granted
Status updated on  22.03.2024
Database last updated on 19.10.2024
FormerGrant of patent is intended
Status updated on  13.11.2023
FormerExamination is in progress
Status updated on  17.10.2023
FormerGrant of patent is intended
Status updated on  04.06.2023
FormerExamination is in progress
Status updated on  12.03.2021
FormerRequest for examination was made
Status updated on  19.07.2019
FormerThe international publication has been made
Status updated on  20.04.2018
Formerunknown
Status updated on  28.11.2017
Most recent event   Tooltip18.10.2024Lapse of the patent in a contracting state
New state(s): GR, PT		published on 20.11.2024 [2024/47]
Applicant(s)For all designated states
GBS Global Biopharma, Inc.
900 Morrison Drive
Suite 200
Ottawa, Ontario K2H 8K7 / CA
[2019/34]
Inventor(s)01 / SMALL-HOWARD, Andrea
GBS Global Biopharma, Inc.
900 Morrison Drive, Suite 200
Ottawa, Ontario K2H 8K7 / CA
02 / TURNER, Helen
GBS Global Biopharma, Inc.
900 Morrison Drive, Suite 200
Ottawa, Ontario K2H 8K7 / CA
 [2024/17]
Former [2019/34]01 / SMALL-HOWARD, Andrea
c/o Global Biopharma, Inc.
900 Morrison Drive, Suite 200
Ottawa, Ontario K2H 8K7 / CA
02 / TURNER, Helen
c/o Global Biopharma, Inc.
900 Morrison Drive, Suite 200
Ottawa, Ontario K2H 8K7 / CA
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2024/17]
Former [2019/34]Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date17800639.110.10.2017
[2019/34]
WO2017US55989
Priority number, dateUS201662406764P11.10.2016         Original published format: US 201662406764 P
[2019/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018071452
Date:19.04.2018
Language:EN
[2018/16]
Type: A1 Application with search report 
No.:EP3525823
Date:21.08.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 19.04.2018 takes the place of the publication of the European patent application.
[2019/34]
Type: B1 Patent specification 
No.:EP3525823
Date:24.04.2024
Language:EN
[2024/17]
Search report(s)International search report - published on:EP19.04.2018
ClassificationIPC:A61K31/015, A61K45/06, A61K31/045, A61K31/352, A61P25/00, A61P25/16, A61K31/05, A61P25/28
[2023/26]
CPC:
A61K31/05 (EP,IL,US); A61K31/015 (EP,IL,US); A61K31/045 (EP,IL,US);
A61K31/352 (EP,IL,US); A61K36/185 (IL,US); A61K45/06 (EP,IL,US);
A61K9/0073 (IL,US); A61K9/0078 (IL,US); A61P25/28 (EP,IL,US);
A61K2300/00 (IL) (-)
C-Set:
A61K31/015, A61K2300/00 (US,EP);
A61K31/045, A61K2300/00 (US,EP);
A61K31/352, A61K2300/00 (EP,US)
Former IPC [2019/34]A61K45/06, A61K31/015, A61K31/045, A61K31/352, A61P25/00, A61P25/16
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/34]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:CANNABINOIDHALTIGE KOMPLEXMISCHUNGEN ZUR BEHANDLUNG DER PARKINSON-KRANKHEIT[2023/50]
English:CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF PARKINSON'S DISEASE[2023/26]
French:MÉLANGES COMPLEXES CONTENANT DES CANNABINOÏDES POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON[2023/50]
Former [2019/34]CANNABINOIDHALTIGE KOMPLEXMISCHUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
Former [2019/34]CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
Former [2019/34]MÉLANGES COMPLEXES CONTENANT DES CANNABINOÏDES POUR LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
Entry into regional phase24.04.2019National basic fee paid 
24.04.2019Designation fee(s) paid 
24.04.2019Examination fee paid 
Examination procedure24.04.2019Examination requested  [2019/34]
24.04.2019Date on which the examining division has become responsible
30.01.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
30.01.2020Despatch of communication of loss of particular rights: Claims {1}
10.02.2020Amendment by applicant (claims and/or description)
15.03.2021Despatch of a communication from the examining division (Time limit: M06)
22.09.2021Reply to a communication from the examining division
28.10.2022Despatch of a communication from the examining division (Time limit: M04)
07.03.2023Reply to a communication from the examining division
05.06.2023Communication of intention to grant the patent
16.10.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.11.2023Communication of intention to grant the patent
14.03.2024Fee for grant paid
14.03.2024Fee for publishing/printing paid
14.03.2024Receipt of the translation of the claim(s)
Request for further processing for:10.02.2020Request for further processing filed
10.02.2020Full payment received (date of receipt of payment)
Request granted
19.02.2020Decision despatched
Fees paidRenewal fee
28.10.2019Renewal fee patent year 03
27.10.2020Renewal fee patent year 04
27.10.2021Renewal fee patent year 05
27.10.2022Renewal fee patent year 06
27.10.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG24.04.2024
FI24.04.2024
HR24.04.2024
NL24.04.2024
NO24.07.2024
GR25.07.2024
IS24.08.2024
PT26.08.2024
[2024/47]
Former [2024/46]BG24.04.2024
FI24.04.2024
HR24.04.2024
NL24.04.2024
NO24.07.2024
IS24.08.2024
Former [2024/44]NL24.04.2024
Cited inInternational search[XY]WO2014145490  (BIOTECH INST LLC [US]) [X] 1-30,34-36,38,41-51,54-60 * page 226, lines 14-16; claims 114-120 * * page 238, paragraph 2 * [Y] 46-65;
 [X]US2016250270  (WENDSCHUH MICHAEL VICTOR [US], et al) [X] 1-10,12,14-22,25,29,30,42-45 * abstract *;
 [E]WO2017193072  (HARVEST DIRECT ENTPR LLC [US]) [E] 1-12,14-29,31,32,38,39,42-48,50-53,55-61,64 * claims 41-58, 61, 64, 68-73, *;
 [Y]  - ETHAN B RUSSO, "Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects : Phytocannabinoid-terpenoid entourage effects", BRITISH JOURNAL OF PHARMACOLOGY, UK, (20110712), vol. 163, no. 7, doi:10.1111/j.1476-5381.2011.01238.x, ISSN 0007-1188, pages 1344 - 1364, XP055420723 [Y] 46-65 * page 1353, column r, paragraph 3 * * page 1353, column lc, paragraph 6 *

DOI:   http://dx.doi.org/10.1111/j.1476-5381.2011.01238.x
 [Y]  - IZZO A A ET AL, "Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 30, no. 10, doi:10.1016/J.TIPS.2009.07.006, ISSN 0165-6147, (20091001), pages 515 - 527, (20090902), XP026639899 [Y] 46-65 * page 522, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.tips.2009.07.006
ExaminationUS2011257256
 GB2492487
 WO2014200350
by applicantUS4511069
 US4778810
 US6080762
 US6403126
 US7052678
 US8277781
 US8895078
 US9066910
    - CALI et al., Cell Tissue Res., (20140000), vol. 357, no. 2, pages 439 - 454
    - KANG et al., Nature Communications, (20120000), vol. 3
    - DOORENBOS et al., "Cultivation, extraction, and analysis of cannabis sativa L.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (19710000), vol. 191, doi:doi:10.1111/j.1749-6632.1971.tb13982.x, pages 3 - 14, XP001055194

DOI:   http://dx.doi.org/10.1111/j.1749-6632.1971.tb13982.x
    - FAIRBAIRN; LIEBMANN, "The extraction and estimation of the cannabinoids in Cannabis sativa L. and its products", JOURNAL OF PHARMACY AND PHARMACOLOGY, (19730000), vol. 25, pages 150 - 155
    - OROSZLAN; VERZAR-PETRI, "Separation, quantitation and isolation of cannabinoids from cannabis sativa L. by overpressured layer chromatography", JOURNAL OF CHROMATOGRAPHY A, (19870000), vol. 388, doi:doi:10.1016/S0021-9673(01)94481-4, pages 217 - 224, XP026729101

DOI:   http://dx.doi.org/10.1016/S0021-9673(01)94481-4
    - M. NAEF et al., "Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans", J. PHARM. SCI., (20040000), vol. 93, doi:doi:10.1002/jps.20037, pages 1176 - 1184, XP008140183

DOI:   http://dx.doi.org/10.1002/jps.20037
    - QI et al., J. Neuroscience, (19970000), vol. 17, no. 4, pages 1217 - 1225
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.